PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting

Journal of Controlled Release

Volumn 162, Issue 2, 2012, Pages 422-428

  Kim, Tae Hyung ^a   Jo, Young Gi ^a   Jiang, Hai Hua ^a   Lim, Sung Mook ^a   Youn, Yu Seok ^a   Lee, Seulki ^b   Chen, Xiaoyuan ^b   Byun, Youngro ^c   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c Seoul National University   (South Korea)

Author keywords

Active tumor targeting; Passive tumor targeting; PEGylation; TRAIL; Transferrin

Indexed keywords

ANTITUMOR EFFECT; ATHYMIC MICE; BIODISTRIBUTIONS; CANCER THERAPY; IN-VIVO; N-TERMINALS; PEGYLATION; RECEPTOR BINDING ASSAYS; SDS-PAGE; SPECIFIC BINDING; TRAIL; TRANSFERRIN; TUMOR ACCUMULATION; TUMOR TARGETING; WESTERN BLOTTING;

CELL DEATH; DRUG PRODUCTS; LIGANDS; MAMMALS; ONCOLOGY; PHARMACOKINETICS;

TUMORS;

MACROGOL; TRANSFERRIN; TRANSFERRIN RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG CARRIERS; HCT116 CELLS; HUMANS; K562 CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTORS, TRANSFERRIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFERRIN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865327124     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.07.021     Document Type: Article

References (25)

1. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155 162
2. L.E. French, and J. Tschopp The TRAIL to selective tumor death Nat. Med. 5 1999 146 147
3. S.Y. Chae, T.H. Kim, K. Park, C.H. Jin, S. Son, S. Lee, Y.S. Youn, K. Kim, D.G. Jo, I.C. Kwon, X. Chen, and K.C. Lee Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand Mol. Cancer Ther. 9 2010 1719 1729
4. T.H. Kim, H.H. Jiang, Y.S. Youn, C.W. Park, S.M. Lim, C.H. Jin, K.K. Tak, H.S. Lee, and K.C. Lee Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution J. Pharm. Sci. 100 2011 482 491
5. T.H. Kim, H.H. Jiang, C.W. Park, Y.S. Youn, S. Lee, X. Chen, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity J. Control. Release 150 2011 63 69
6. H. Xiang, C.B. Nguyen, S.K. Kelley, N. Dybdal, and E. Escandón Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice Drug Metab. Dispos. 32 2004 1230 1238
7. M. Jo, T.H. Kim, D.W. Seol, J.E. Esplen, K. Dorko, T.R. Billiar, and S.C. Strom Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat. Med. 6 2000 564 567
8. S.K. Kelley, L.A. Harris, D. Xie, L. Deforge, K. Totpal, J. Bussiere, and J.A. Fox Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmacol. Exp. Ther. 299 2001 31 38
9. T.H. Kim, Y.S. Youn, H.H. Jiang, S. Lee, X. Chen, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects Bioconjug. Chem. 22 2011 1631 1637
10. H.H. Jiang, T.H. Kim, S. Lee, X. Chen, Y.S. Youn, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy Biomaterials 32 2011 8529 8537
11. S. Lee, Y.S. Youn, S.H. Lee, Y. Byun, and K.C. Lee PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice Diabetologia 49 2006 1608 1611
12. Y.S. Youn, M.J. Kwon, D.H. Na, S.Y. Chae, S. Lee, and K.C. Lee Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection J. Control. Release 125 2008 68 75
13. J.S. Kang, P.P. DeLuca, and K.C. Lee Emerging PEGylated drugs Expert Opin. Emerg. Drugs 14 2009 363 380
14. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 55 2003 1261 1277
15. P.T. Gomme, K.B. McCann, and J. Bertolini Transferrin: structure, function and potential therapeutic actions Drug Discov. Today 10 2005 267 273
16. Z.M. Qian, H. Li, H. Sun, and K. Ho Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 54 2002 561 587
17. M. Fritzer, T. Szekeres, V. Szüts, H.N. Jarayam, and H. Goldenberg Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells Biochem. Pharmacol. 51 1996 489 493
18. U. Beyer, T. Roth, P. Schumacher, G. Maier, A. Unold, A.W. Frahm, H.H. Fiebig, C. Unger, and F. Kratz Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil J. Med. Chem. 41 1998 2701 2708
19. M. Kursa, G.F. Walker, V. Roessler, M. Ogris, W. Roedl, R. Kircheis, and E. Wagner Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer Bioconjug. Chem. 14 2003 222 231
20. L. Citores, J.M. Ferreras, R. Muñoz, J. Benítez, P. Jiménez, and T. Girbés Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l Cancer Lett. 184 2002 29 35
21. P.R. Dash, M.L. Read, K.D. Fisher, K.A. Howard, M. Wolfert, D. Oupicky, V. Subr, J. Strohalm, K. Ulbrich, and L.W. Seymour Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin J. Biol. Chem. 275 2000 3793 3802
22. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763
23. M. Singh, H. Atwal, and R. Micetich Transferrin directed delivery of adriamycin to human cells Anticancer Res. 18 1998 1423 1427
24. A. Bérczi, M. Ruthner, V. Szüts, M. Fritzer, E. Schweinzer, and H. Goldenberg Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis Eur. J. Biochem. 213 1993 427 436
25. Y.Y. Jiang, C. Liu, M.H. Hong, S.J. Zhu, and Y.Y. Pei Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation Bioconjug. Chem. 18 2007 41 49